BC Extra | Aug 7, 2019
Clinical News

Rhythm data sets up submissions for ultra-rare obesity disorders

Two new Phase III readouts pave the way for Rhythm Pharmaceuticals to make its first regulatory submissions for setmelanotide to treat rare genetic disorders that result in obesity. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Wednesday that...
BC Extra | Jun 21, 2019
Company News

June 21 Company Quick Takes: FDA rejects Daiichi's AML candidate; plus Sanofi, Novartis and more

Complete response letter for Daiichi's quizartinib  Daiichi Sankyo Co. Ltd. (Tokyo:4568) said FDA issued a complete response letter for quizartinib, its candidate to treat relapsed/refractory FLT3-ITD-positive acute myelogenous leukemia (AML). In May, an FDA advisory...
BC Week In Review | Jun 22, 2018
Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million on June 20 through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is...
BC Extra | Jun 21, 2018
Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is an 8% discount...
BC Extra | Mar 20, 2018
Preclinical News

Rhythm estimates mutations in genes tied to obesity

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) presented an analysis of genetic epidemiology data at the Endocrine Society meeting in Chicago suggesting that about 12,800 Americans are homozygous or compound heterozygous for known and predicted loss-of-function variants in...
BC Week In Review | Dec 8, 2017
Clinical News

Rhythm reports Phase II data of setmelanotide to treat Bardet-Biedl Syndrome

In October, Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) reported preliminary data from 5 Bardet-Biedl Syndrome patients with morbid obesity and hyperphagia in the Phase II portion of a Phase II/III trial showing that setmelanotide (RM-493) reduced body...
BC Week In Review | Oct 6, 2017
Financial News

Rhythm rises on $119.9M IPO

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) gained 76% in its first day of trading on Oct. 5 after raising $119.9 million through the sale of 7.1 million shares at $17 in a bumped-up IPO underwritten by Morgan...
BC Extra | Oct 5, 2017
Financial News

Rhythm rises on $119.9M IPO

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) gained $13 (76%) to $30 in its first day of trading Thursday after raising $119.9 million through the sale of 7.1 million shares at $17 in a bumped-up IPO underwritten by...
BC Week In Review | Sep 8, 2017
Company News

Fosun gains rights to bremelanotide in China and Taiwan from Palatin

Palatin Technologies Inc. (NYSE-M:PTN) granted Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive rights to develop and commercialize bremelanotide in China, including Hong Kong and Macau, and Taiwan to treat hypoactive sexual desire disorder...
BC Week In Review | May 19, 2017
Clinical News

FDA grants breakthrough therapy designation to setmelanotide for obesity

Rhythm Holding Co. LLC (Boston, Mass.) said FDA granted breakthrough therapy designation to setmelanotide (RM-493) to treat obesity associated with genetic defects upstream of the melanocortin 4 receptor (MC4R) in the leptin-melanocortin pathway, including leptin...
Items per page:
1 - 10 of 118